TCGA-A7-A5ZX-01A-12R-A29R-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 11
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.430
- MYOGENESIS+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
- HEDGEHOG_SIGNALING+0.200
- APICAL_JUNCTION+0.180
- NOTCH_SIGNALING+0.180
- COAGULATION+0.160
- P53_PATHWAY+0.160
- UV_RESPONSE_DN+0.150
- PANCREAS_BETA_CELLS+0.120
Top 10 suppressed
- E2F_TARGETS-0.620
- G2M_CHECKPOINT-0.590
- MTORC1_SIGNALING-0.570
- INTERFERON_GAMMA_RESPONSE-0.540
- MYC_TARGETS_V2-0.540
- INTERFERON_ALPHA_RESPONSE-0.530
- MYC_TARGETS_V1-0.460
- ALLOGRAFT_REJECTION-0.450
- INFLAMMATORY_RESPONSE-0.420
- MITOTIC_SPINDLE-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AC-A3W7-01A-11R-A22K-07 | — | A | 0.933 |
| 2 | SRR1313111 | — | A | 0.913 |
| 3 | TCGA-A7-A426-01A-22R-A24H-07 | — | A | 0.911 |
| 4 | TCGA-W8-A86G-01A-21R-A36F-07 | — | A | 0.907 |
| 5 | AUR-AFUN-TTM1-A-1-0-R-A743-41 | — | A | 0.905 |
| 6 | C3L-02165 | — | cohortA2 | 0.903 |
| 7 | TCGA-56-8624-01A-11R-2403-07 | — | cohortSQ1 | 0.891 |
| 8 | C3N-01409 | — | cohortA1 | 0.886 |
| 9 | TCGA-BH-A28O-01A-11R-A22K-07 | — | A | 0.880 |
| 10 | SRR25617847 | — | C | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.430 | Inavolisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.180 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| COAGULATION | 0.160 | Binimetinib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.150 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.120 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.090 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.020 | Inavolisib | — uncovered |